Where does Context Biopharma, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Context Biopharma, Inc. ranks #45,857 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Context Biopharma, Inc. hold?

Context Biopharma, Inc. holds 5 US utility patents granted between 2019 and 2023, spanning 4 technology areas.

What is Context Biopharma, Inc.'s Innovation Score?

Context Biopharma, Inc. has an Innovation Score of 27.3 out of 100 (23rd percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Context Biopharma, Inc. focus on?

Context Biopharma, Inc.'s top technology area is C07J (Steroids) with 3 patents. Grants appear in 4 CPC subclasses total.

Is Context Biopharma, Inc.'s patent grant rate increasing or decreasing?

Context Biopharma, Inc.'s recent grant velocity is +300% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Context Biopharma, Inc.'s patents?

Context Biopharma, Inc.'s patents average 16.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Context Biopharma, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Context Biopharma, Inc.

USPTO PatentsView assignee record - 5 granted patents across 4 technology areas, recorded in grant years 2019–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07J (Steroids).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Context ranks #45,857 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 4 technology areas.

#45,857
of 49,997 US assignees by volume: 23rd percentile
by Innovation Score (27.3/100): 16.0
avg claims per patent: +300%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R45857 · US Corporation #45,857 · 5 grants

GRANTS-MICRO · BOTTOM-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 5 grants
BOTTOM-DECILE #45,857/49,997
PHOTO-FINISH Constellium Valais ()
CPC-NARROW C07J · 4 areas
INNOV-THIN 27.3/100
CLAIMS-RICH 16.0 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +300% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Constellium Valais SA (LTD) (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Context Biopharma · this assignee

27
3D Lighting… · lowest

7

What this shows Context's Innovation Score is 27.3/100 (23rd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Context's grants concentrate

Context Biopharma, Inc. is a focused PatentsView assignee: 4 CPC subclasses with 60% of grants classified under C07J (Steroids). Peak complete grant year is 2020 (2 grants) versus a trough of 1 in 2019. By volume, Context sits between Constellium Valais SA (LTD) and Cookgas, LLC.

Context's three-year grant acceleration

Context Biopharma, Inc. shows 2 grants in 2022–2024 against only 3 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Constellium Valai…

5
Contact Control I…

5
Contactengine

5
Contec Medical Sy…

5
Conteyor Internat…

5
Contour Semicondu…

5
Coocon

5
Cookgas

5
Context Biopharma ◀

5

What this shows Context holds 5 patents at rank #45,632, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Context

By rank, the assignees closest to #45,632 in granted patent volume.

Leaders in C07J (Steroids)

Other assignees with the most granted patents in Context's primary technology class.

Context's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

27 23rd percentile higher than 23% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2019–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.

View data table

Context Biopharma, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2019	1	20.0%
2020	2	40.0%
2023	2	40.0%

Which technologies does Context Biopharma, Inc. patent most?

C07J - Steroids 3

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 3

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 3

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 1

Top 4 of 4 technology areas

Where it ranks

Overall rank by patents

#45,857

of 49,997 tracked assignees

Innovation Score

27.3 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Context Biopharma, Inc.'s patent record in context - here's where to go next.

Context Biopharma, Inc.'s lead technology class is C07J (Steroids), 60% of its portfolio - see every assignee active in that class. Explore C07J
Ranked #45,857 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Context Biopharma, Inc. against Constellium Valais SA (LTD), an assignee filing at a similar volume. Compare portfolios
Innovation Score of 27.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.